Biogen Inc. shares declined 0.6% in premarket trade Wednesday after the company said its therapy failed to meet primary and secondary efficacy endpoints in a phase 2b trial for acute ischemic stroke. More detailed results from the trial will be made public in a future scientific forum, the company said. The results do not affect the therapy’s currently-approved indications, such as multiple sclerosis, Biogen said. The company did not say if it would continue developing natalizumab, though it did say it plans to study another compound, BIIB093, in large hemispheric infarction mid-year. Biogen shares have surged 6.2% over the last three months, compared with a 4% rise in the S&P 500 and a 5.8% rise in the Dow Jones Industrial Average .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News